News Releases

ROCKVILLE, Md. and SHANGHAI , Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies

Significant progress made year-to-date on key clinical assets: ‐         Uliledlimab  (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐         Givastomig  (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including

ROCKVILLE, Md. and SHANGHAI , Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate

GAITHERSBURG, Md. and SHANGHAI , July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering  immunotherapies, today announced the publication of a manuscript entitled

GAITHERSBURG, Md. and SHANGHAI , June 22, 2023 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr.

-  Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells. -  In newly diagnosed patients who were not eligib le for or declined chemotherapy treatment, 63% o f the patient s with CD73 High  and

GAITHERSBURG, Md. and SHANGHAI , May 1, 2023 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form

GAITHERSBURG, Md. and SHANGHAI , April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to Tracon

GAITHERSBURG, Md. and SHANGHAI , April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational